HARBIN, China, April 20 RenhuangPharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), adeveloper, manufacturer and distributor of botanical products,bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announcedthe appointment of Dr. Changxiong Sun and Mr. Bingchun Wu to its Board ofDirectors as independent directors effective April 19. Dr. Sun and Mr. Wuwill join the Company's Audit Committee, which is chaired by independentdirector Mr. Sean Shao.
"We extend a warm welcome to Dr. Sun and Mr. Wu as they join our Board asindependent directors. The appointments reflect Renhuang's commitment to thehighest standards of corporate governance," said Mr. Shaoming Li, Chairman andCEO of Renhuang Pharmaceuticals. "Dr. Sun is a noted expert on managementissues, while Mr. Wu brings a lifetime of experience in Chinese medicine toRenhuang's board. We look forward to working with them as we continue tobuild Renhuang to be the world leader in natural therapeutics for treatingdepression, melancholy and nerve regulation."
Dr. Sun is a professor of Management Science and Engineering, and adoctoral tutor at the School of Management of Harbin Institute of Technology,one of China's leading universities. Dr. Sun has previously served in seniormanagerial positions with companies in the private and public sector. He hasalso served as deputy Secretary General of the Harbin Municipal GovernmentCommittee from 2004 to 2005. Dr. Sun holds a PhD from Harbin Institute ofTechnology.
Mr. Wu has been the Team Leader of Chinese Medicine Research Group at theHeilongjiang Province Chinese Medicine Research Institute. Mr. Wu also servedas the Chief Expert of Chinese Medicine at the Heilongjiang Province Scienceand Technology Department. Prior to that, he was Director of the ChineseMedicine Pharmacology Research Office. Mr. Wu holds a Bachelor's degree inPharmacy Science from China Medical College and a degree in Finance fromHarbin University of Commerce.
ABOUT RENHUANG PHARMACEUTICALS, INC.
Renhuang Pharmaceuticals, Inc. is engaged in the research, development,manufacturing, and distribution of botanical products, bio-pharmaceuticalproducts, and traditional Chinese medicines ("TCM"), in the People's Republicof China. All of the Company's products are produced at its threeGMP-certified production facilities in Ah City, Dongfanghong and Qingyang.The Company distributes its botanical anti-depression and nerve-regulationproducts, biopharmaceutical products, and botanical antibiotic and OTC TCMsthrough its network of over 3,000 distributors and over 70 sales centersacross 24 provinces in China.
Safe Harbor Statement
This press release contains certain statements that may includeforward-looking statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995. Such statements are based upon management'sbeliefs, assumptions and expectations of the Company's future operations andeconomic performance, taking into account the information currently availableto management. These statements are not statements of historical fact.Forward-looking statements involve risks and uncertainties, some of which arenot currently known that may cause actual results, performance or financialcondition to be materially different from the expectations of future results,performance or financial condition expressed or implied in any forward-lookingstatements. These forward-looking statements are based on current plans andexpectations and are subject to a number of uncertainties including, but notlimited to, the Company's ability to achieve its financial guidance, abilityto list its shares on a senior stock exchange, ability to manage expansion ofits operations effectively, competition in the marketing and sales of itsproducts, and other factors detailed in the Company's annual report on Form10-K and other filings with the Securities and Exchange Commission. TheCompany undertakes no obligation to publicly update or revise anyforward-looking statements, whether as a result of new information, futureevents or otherwise. You are cautioned not to unduly rely on suchforward-looking statements when evaluating the information presented herein.For more information, please contact: Renhuang Pharmaceuticals, Inc. Ms. Portia Tan, IR Contact Phone: +86-451-5392-5461 Email: firstname.lastname@example.org CCG Investor Relations: Ms. Lei Huang, Account Manager Phone: +1-646-833-3417 (New York) Email: email@example.com Web: http://www.ccgirasia.com Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: firstname.lastname@example.org
SOURCE Renhuang Pharmaceuticals, Inc.